For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 41,484 | 29,416* | ||
| General and administrative | 17,736 | 12,161* | ||
| Total operating expenses | 59,220 | 41,577 | ||
| Loss from operations | -59,220 | -41,577* | ||
| Interest income | 3,457 | 2,740* | ||
| Interest expense | 1,245 | 1,371* | ||
| Foreign exchange loss, net | -44 | -33* | ||
| Change in fair value of 2022 usd financing warrants | 20,046 | 5,708* | ||
| Gain on extinguishment of contribution payable | - | 0* | ||
| Total other income/(expense) | -17,878 | -4,371* | ||
| Net loss | -77,098 | -45,948* | ||
| Unrealized gain/(loss) on investments | -262 | 83* | ||
| Gain/(loss) on foreign currency translation | 1 | -16* | ||
| Comprehensive loss | -77,359 | -45,882 | ||
| Basic EPS | -0.71 | -0.514 | ||
| Diluted EPS | -0.71 | -0.514 | ||
| Basic Average Shares | 108,790,941 | 89,327,608 | ||
| Diluted Average Shares | 108,790,941 | 89,327,608 | ||
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)